



## Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

Francesco Merli <sup>a,\*</sup>, Federica Cavallo <sup>b</sup>, Flavia Salvi <sup>c</sup>, Alessandra Tucci <sup>d</sup>, Gerardo Musuraca <sup>e</sup>, Luca Nassi <sup>f</sup>, Michele Merli <sup>g</sup>, Monica Tani <sup>h</sup>, Guido Gini <sup>i</sup>, Angela Ferrari <sup>a</sup>, Anna Lia Molinari <sup>j</sup>, Anna Marina Liberati <sup>k</sup>, Annarita Conconi <sup>l</sup>, Paola Matteucci <sup>m</sup>, Alessia Bari <sup>n</sup>, Renato Scalone <sup>o</sup>, Simone Ferrero <sup>b</sup>, Manuela Zanni <sup>c</sup>, Caterina Mammi <sup>p</sup>, Stefano Luminari <sup>a,q</sup>

<sup>a</sup> Hematology Unit, Arcispedale S.Maria Nuova, Azienda Unità Sanitaria Locale – IRCCS, Reggio Emilia, Italy

<sup>b</sup> Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/AOU “Città della Salute e della Scienza di Torino”, Torino, Italy

<sup>c</sup> Hematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy

<sup>d</sup> Hematology, Spedali Civili Hospital, Brescia, Italy

<sup>e</sup> Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

<sup>f</sup> Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Azienda Ospedaliero-Universitaria Maggiore della Carità Novara, Italy

<sup>g</sup> Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy

<sup>h</sup> Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy

<sup>i</sup> Division of Hematology, Ospedali Riuniti, Ancona, Italy

<sup>j</sup> Hematology, Ospedale degli Infermi, Rimini, Italy

<sup>k</sup> Division of Onco-Hematology, S.Maria Terni Hospital, Department of Surgery and Medical Sciences, University of Perugia, Terni, Italy

<sup>l</sup> Unit of Hematology, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy

<sup>m</sup> Haematology and Bone Marrow Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

<sup>n</sup> Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy

<sup>o</sup> Division of Hematology, La Maddalena Hospital, Palermo, Italy

<sup>p</sup> Gruppo Amici dell'Ematologia GRADE- Onlus Foundation, Reggio Emilia, Italy

<sup>q</sup> Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, University of Modena and Reggio Emilia, Reggio Emilia, Italy

### ARTICLE INFO

#### Article history:

Received 3 January 2019

Received in revised form 5 June 2019

Accepted 27 June 2019

Available online 8 July 2019

#### Keywords:

Diffuse large B-cell lymphoma

Older adult patients

Comprehensive geriatric assessment

Unfit

Adapted immunochemotherapy

Obinutuzumab-miniCHOP

### ABSTRACT

**Objective:** To evaluate activity and safety of obinutuzumab-miniCHOP (Ga101-miniCHOP) combination in older patients with Diffuse Large B-Cell Lymphoma (DLBCL) unfit to receive full dose immunochemotherapy.

**Materials and Methods:** We conducted a Simon's two-stage phase II multicenter trial to investigate response rate (primary endpoint) and safety of six courses of Ga101-miniCHOP in older patients with DLBCL (≥65 years), prospectively defined as unfit according to a simplified Comprehensive Geriatric Assessment (sCGA).

**Results:** Overall, 34 patients were enrolled (median age 82 years; range 68–89), with 27 out of the 33 eligible patients completing all six planned courses. Complete Remission (CR) rate was reported in fourteen patients (42%). After a median follow-up of sixteen months, the two-year Progression Free and Overall Survival (PFS and OS) were 49% (95% Confidence Interval (CI), 28 to 67) and 68% (95% CI, 49 to 81), respectively. The most frequent grade 3–4 adverse event was neutropenia in thirteen patients (26%).

**Conclusions:** Based on the observed CR rate, study accrual was interrupted due to the very low probability of demonstrating the initial study hypothesis that Ga101-miniCHOP could improve results of historical data obtained with R-miniCHOP in this group of patients. Nonetheless, results achieved with the 33 treated patients confirm activity and good tolerability of the Ga101-miniCHOP regimen for older unfit adult patients with DLBCL.

© 2019 Published by Elsevier Ltd.

### 1. Introduction

Treatment of very old or unfit patients with Diffuse Large B-Cell Lymphoma (DLBCL) is challenging due to the presence of comorbidities or concomitant medical or physical conditions which are frequent in elderly patients and which limit available therapeutic options. Combination of rituximab with full dose CHOP (cyclophosphamide,

\* Corresponding author at: Hematology Unit, Arcispedale S.Maria Nuova, Azienda Unità Sanitaria Locale – IRCCS Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy.  
E-mail address: merli.francesco@ausl.re.it (F. Merli).

doxorubicin, vincristine, and prednisone) chemotherapy is the undisputed standard treatment for all patients, including elderly subjects, but it is not usually prescribed in patients who are older than 80 years or in those who are not fit enough to receive full dose chemotherapy. An attenuated version of R-CHOP, namely R-miniCHOP, has been recommended as standard regimen for patients older than 80 years based on the positive results of a large phase II study [1,2]. Obinutuzumab (Ga101) is a glycoengineered, type II anti-CD20 monoclonal antibody with greater direct cell death induction and antibody-dependent cellular cytotoxicity and phagocytosis than rituximab [3]. In parallel with the identification of the most active immunochemotherapy regimen similar efforts are required to grant for an accurate and objective pre-treatment selection of the older patient with DLBCL in order to optimize risk to benefit ratio of treatment. We conducted a prospective phase II study (FIL\_GAEL Study; [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02495454) Identifier: NCT02495454) to evaluate activity and safety of Ga101-miniCHOP combination in older patients with DLBCL who were prospectively defined as unfit according to a simplified Comprehensive Geriatric Assessment (sCGA) [4].

## 2. Methods

The study was approved by local Ethics Committee and Institutional Review Board of each participating centres and registered on [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02495454) with number NCT02495454.

Older adults ( $\geq 65$  years) with a newly diagnosed DLBCL were considered eligible if they were unfit on the sCGA. Simplified CGA was performed during staging procedures, after written informed consent, through application of the following instruments: comorbidity score according to the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) [5]; the Index of Independence in Activities of Daily Living (ADL) [6]; the Instrumental Activity of Daily Living (IADL) scale [7].

Patients were classified as unfit with different criteria according to age: for patients aged  $\geq 80$  years old; no limitations in ADL and IADL scores, no grade 3–4 comorbidities and less than five grade 2 comorbidities at CIRS-G were required. Patients younger than 80 years were classified as unfit with a at least one of the following; ADL score of 5, IADL score of 6–7, 5 to 8 grade-2 comorbidities without any grade 3–4 comorbidity at CIRS-G [4]. Frail patients, as per Tucci et al., [4] and patients with transformed lymphoma were excluded.

Patients received miniCHOP (400 mg/m<sup>2</sup> cyclophosphamide, 25 mg/m<sup>2</sup> doxorubicin, 1 mg vincristine on day 1 of each cycle, and 40 mg/m<sup>2</sup> prednisone on days 1–5 every 21 days), combined with obinutuzumab 1000 mg on days 1,8, and 15 of cycle one, and on day 1 of subsequent cycles. Treatment plan consisted of six cycles of Ga101-miniCHOP followed by two additional doses of Ga101, every 21 days. The use of G-CSF was mandatory.

The primary endpoint was Complete Response Rate (CRR) according to Cheson 1999 criteria [8]. Secondary endpoints included assessment of adverse events (AE), response rate according to Cheson 2007 criteria [9], Overall Response Rate (ORR), Overall Survival (OS), and Progression-Free Survival (PFS). The sample size was estimated according to Simon's optimal two-stage design. The study was designed to assess whether Ga101-miniCHOP could increase the CRR compared to historical data. The null hypothesis ( $p_0$ ) was set at 0.60 on the basis of Peyrade et al.'s findings [1] and the alternative hypothesis ( $p_1$ ) was set at 0.75, with type I and II errors of 10% and 90%. A total of 71 patients were required, with at least 48 in complete remission (CR), to draw a conclusion on the efficacy of treatment. The second stage could be activated with at least 22 CR out of the first 34 patients. Analysis was by intention to treat. Here we report the results of the first stage.

## 3. Results and Discussion

From August 2015 to June 2016, 34 patients were enrolled by sixteen Italian centers: one patient was subsequently excluded due to violation of inclusion criteria (Richter syndrome) (Table 1). Overall, 228 cycles were delivered, with 27/33 patients completing all six planned courses; four patients interrupted treatment because of AEs and two because of lack of response. Adverse events that caused treatment interruption included infection in two cases, hepatic toxicity and worsening of performance status in one case each. Treatment delays were reported in 34 out of 228 delivered cycles and were evenly distributed among cycles. Final response was reported as complete in fourteen patients (42%), and partial in eight (24%); ten patients had stable or progressive disease (30%) and one patient (3%) was not assessed for response. 2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) was used in 25 patients to define response; complete metabolic response was observed in seventeen cases. Thirty-three patients experienced AEs (details are provided in Table 2). An adverse event leading to death was reported in one patient (heart failure in a patient in CR five months after the last dose of chemotherapy).

After a median follow-up of sixteen months, eighteen patients experienced lymphoma progression, one relapsed, and ten died (nine due to lymphoma progression, and one due to AE during follow up in CR). The two-year PFS and OS were 49% (95% Confidence interval (CI), 28 to 67) and 68% (95% CI 49 to 81), respectively. Based on the observed CR rate, study accrual was interrupted due to the very low probability of demonstrating the initial study hypothesis that Ga101-miniCHOP could improve results of historical data obtained with R-miniCHOP in this group of patients. Nonetheless, results achieved with the 33 treated patients in first stage are available to confirm activity and good tolerability of the Ga101-miniCHOP regimen for older unfit patients affected by DLBCL.

These results are consistent with those from the recently published randomized Goya trial [10], which compared Ga101-CHOP

**Table 1**

Characteristics of patients enrolled in the study (N = 33) and summary of study endpoints.

		N	%
<b>Clinical features</b>			
Age	Median (range)	82	(68–89)
	$\geq 80$ years	23	70
Gender	Male	19	55
Stage	III-IV	27	81
ECOG PS	2	2	6
LDH	>UNL	23	70
IPI	3–5	21	64
<b>Geriatric assessment</b>			
Unfit patients for age		23	70
ADL = 5		6	18
IADL = 7–6		1	3
ADL + IADL		2	6
CIRS grade-2 comorbidities (N = 5–8)		1	3
Cardiac comorbidity grade 1–2		18	54
<b>Treatment activity and survival</b>			
Response	CR rate	14	42
	PR rate	8	24
	SD/PD	10	30
	Not evaluable	1	3
2-year PFS	% (95% CI)	49%	(28 to 67)
2-year OS	% (95% CI)	68%	(49 to 81)

ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; ADL, Activity of Daily Living; IADL, Instrumental Activity of Daily Living (IADL), CIRS-G, Cumulative Illness Rating Scale – Geriatric; CR, Complete Remission; PR, Partial Remission; SD, Stable Disease; PD, Progressive Disease; PFS, Progression Free Survival; OS, Overall Survival; CI, Confidence Interval.

**Table 2**  
Summary of hematological and extra-hematological adverse events.

Adverse event (N = 33)	Grade 1–2		Grade 3–4	
	N	%	N	%
<b>Hematological</b>				
Anemia	6	18	–	–
Leucopenia	2	6	2	6
Neutropenia	2	6	13	26
Thrombocytopenia	10	30	1	3
<b>Extra-hematological</b>				
Cardiac disorders	3	9	2	6
Gastrointestinal disorders	11	33	1	3
Hepatobiliary disorders	–	–	2	6
General disorders	4	12	2	6
Infections and infestations	6	18	1	3
Injury/poisoning/ Procedural complications	–	–	2	6
Investigations	2	6	1	3
Metabolism and nutrition disorders	5	15	3	9
Musculoskeletal - connective tissue dis.	5	15	3	6
Neoplasms benign, malignant and unsp.	–	–	2	6
Nervous system disorders - psychiatric dis.	6	18	1	3
Renal and urinary disorders	2	6	–	–
Respiratory/thoracic and mediastinal	5	15	–	–
Vascular	1	3	–	–
Other	8	24	–	–

Legend to table: dis, disease; unsp, unspecified.

with standard R-CHOP in 1418 previously untreated DLBCL patients and which was not able to demonstrate superiority of Ga101 chemotherapy. The Goya results and those from our small study suggest that the increase in treatment efficacy in DLBCL likely cannot be achieved by potentiating the anti-CD20 monoclonal antibody part of therapy. This observation is also confirmed by the results of a phase II study where rituximab was substituted with ofatumumab, another second generation anti-CD20 antibody, and combined with mini-CHOP in 120 DLBCL patients older than 80 years [11]. Although a formal comparison between the two phase II studies is not appropriate, Peyrade et al. achieved similar results with ofatumumab (Ofa) or rituximab combined with miniCHOP, and the greatest improvement in the Ofa-miniCHOP study was likely an effect of the adoption of a mandatory pre-phase therapy with steroids and vincristine that actually reduced the rate of early fatal events.

Regarding the prospective use of sCGA this work is part of a larger project for older patients with DLBCL for whom a preliminary sCGA is required to define patient fitness status and to adapt treatment goals. This project is conducted by the FIL (Fondazione Italiana Linfomi) as an observational study (NCT02364050), with about 1400 enrolled patients with the aim to validate the use of sCGA and to define separate groups of patients to enroll into dedicated clinical trials. Patients prospectively enrolled in this so-called “Elderly Project” were categorized into one of three groups namely FIT, UNFIT and FRAIL. FIT patients were then offered a standard R-CHOP treatment or clinical trials with curative intent; UNFIT patients were better candidates for adapted R-CHOP regimens, or to dedicated clinical trials, like the Ga101-miniCHOP used in this trial. Finally FRAIL patients were offered low toxic regimens or clinical trials with palliative intent. To the best of our knowledge the elderly project is the first attempt to try to objectify and standardize treatment choices and goals of older patients with DLBCL and to better approach clinical research in this population.

#### 4. Conclusions

In conclusion, our phase II study confirmed the activity and safety of Ga101-miniCHOP for the treatment of older, unfit patients with DLBCL, but was not able to show it as a promising regimen to challenge the current standard R-miniCHOP. To improve treatment efficacy in this

hard-to-treat patient population, different strategies should be adopted that include better patient and/or lymphoma profiling and the use of new drugs with a novel non-cross-resistant mechanism of action.

#### Funding Sources

This study was sponsored by the Fondazione Italiana Linfomi-ONLUS (nonprofit organization).

Roche S.p.a. provided study drug and research financial support for the study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

#### Author Contribution

Study concepts: Francesco Merli; Stefano Luminari.

Study design: Francesco Merli; Stefano Luminari.

Data acquisition: Federica Cavallo; Flavia Salvi; Alessandra Tucci; Gerardo Musuraca; Luca Nassi; Michele Merli; Monica Tani; Guido Gini; Angela Ferrari; Anna Lia Molinari; Anna Marina Liberati; Annarita Conconi; Paola Matteucci; Alessia Bari; Renato Scalone; Simone Ferrero; Manuela Zanni.

Quality control of data and algorithms: Stefano Luminari; Caterina Mammi.

Data analysis and interpretation: Francesco Merli; Stefano Luminari.

Statistical analysis: Stefano Luminari; Caterina Mammi.

Manuscript preparation: Francesco Merli; Stefano Luminari.

Manuscript editing: Francesco Merli; Stefano Luminari.

Manuscript review: Francesco Merli; Federica Cavallo; Flavia Salvi; Alessandra Tucci; Gerardo Musuraca; Luca Nassi; Michele Merli; Monica Tani; Guido Gini; Angela Ferrari; Anna Lia Molinari; Anna Marina Liberati; Annarita Conconi; Paola Matteucci; Alessia Bari; Renato Scalone; Simone Ferrero; Manuela Zanni; Caterina Mammi; Stefano Luminari.

#### Declarations of Competing Interest

Francesco Merli holds a consultancy/advisory role from Roche, Gilead, Takeda, Janssen, Celgene, and Mundipharma.

Stefano Luminari holds a consultancy/advisory role from Roche, Celgene, Sandoz and Gilead.

Simone Ferrero holds a consultancy/advisory role and speakers honoraria from Janssen, advisory role and speakers honoraria from Pfizer, and speakers honoraria from Gilead.

The remaining authors declare no competing financial interests.

#### Acknowledgments

The authors thank the patients and their families for participating in this study; the team of Uffici Studi FIL for protocol support, start-up and data management; the coinvestigators, and study coordinators at each of the sites, and Jaqueline Costa for reviewing the manuscript.

#### References

- [1] Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2011;12:460–8.
- [2] Buske C, Hutchings M, Ladetto M, et al. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. *Ann Oncol* 2018;29:544–62.
- [3] Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. *Mol Cancer Ther* 2013;12:2031–42.
- [4] Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the lymphoma Italian foundation (FIL). *Leuk Lymphoma* 2015;56:921–6.

- [5] Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. *J Am Geriatr Soc* 1995;43:130–7.
- [6] Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. *JAMA* 1963;185:914–9.
- [7] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 1969;9:179–86.
- [8] Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol* 1999 Apr;17(4):1244.
- [9] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007 Feb 10;25(5):579–86.
- [10] Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol* 2017;35:3529–37.
- [11] Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. *Lancet Haematol* 2017;4:e46–55.